# Chemed Corp: Form 10-Q for the period ended Mar 31, 2012

- Company: [Chemed Corp](/companies/che.md) (CIK 19584)
- Form: 10-Q
- Filed: 2012-04-30
- Accepted by EDGAR: Apr 30, 2012, 12:44 ET
- Period: 2012-03-31
- Accession: 0001157523-12-002249
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/19584/000115752312002249/a50244238.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/19584/000115752312002249/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-01-01 to 2012-03-31 | $352.9m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2012-01-01 to 2012-03-31 | $257.4m | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2012-01-01 to 2012-03-31 | $53.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2012-01-01 to 2012-03-31 | $35.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-01-01 to 2012-03-31 | $3.6m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-01-01 to 2012-03-31 | $13.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-01-01 to 2012-03-31 | $20.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-01-01 to 2012-03-31 | $1.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-01-01 to 2012-03-31 | $1.08 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-01-01 to 2012-03-31 | 19,353,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2012-01-01 to 2012-03-31 | $10.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2012-01-01 to 2012-03-31 | $12.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2012-01-01 to 2012-03-31 | $3.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2012-03-31 | $34.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-03-31 | $177.3m | us-gaap:AssetsCurrent |
| Total assets | at 2012-03-31 | $831.5m | us-gaap:Assets |
| Current liabilities | at 2012-03-31 | $155.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-03-31 | $397.0m | us-gaap:Liabilities |
| Long-term debt | at 2012-03-31 | $168.8m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2012-03-31 | $434.5m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2012-03-31 | 19,228,654 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 28,249 characters.

### Executive Summary

We operate through our two wholly owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

|  | Three months ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| Service revenues and sales | **$352,943** | $330,918 |
| Net income | **$20,445** | $18,101 |
| Diluted EPS | **$1.06** | $0.84 |
| Adjusted EBITDA | **$46,340** | $45,618 |
| Adjusted EBITDA as a % of revenue | **13.1%** | 13.8% |

Earnings before interest, taxes, depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP. We use Adjusted EBITDA as a measure of earnings for our long-term incentive plan awards. We provide EBITDA and Adjusted EBITDA to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements. Our EBITDA and Adjusted EBITDA should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our net income to our EBITDA and Adjusted EBITDA is presented on page 23.

For the three months ended March 31, 2012, the increase in consolidated service revenues and sales was driven by a 10.7% increase at VITAS partially offset by a 3.3% decrease at Roto-Rooter. The increase in service revenues at VITAS was a result of increased average daily census (“ADC”) of 6.1%, driven by an increase in admissions of 3.3% and a 4.4% increase in average length of stay, combined with Medicare price increases of approximately 2.5%. The decrease in service revenues at Roto-Rooter was driven by a 6.1% decrease in job count partially offset by a 2.5% price and mix shift increase. The remaining change in Roto-Rooter revenue is related mainly to our independent contractor operations. Consolidated net income increased 12.9%. Diluted EPS increased 26.2% as a result of the increase in net income and a lower number of shares outstanding. Adjusted EBITDA as a percent of revenue decreased 0.7% as a result of the decrease in service revenues at Roto-Rooter. See page 24 for additional VITAS operating metrics.

VITAS expects to achieve full-year 2012 revenue growth, prior to Medicare cap, of 5.0% to 8.0%. Admissions are estimated to increase approximately 2.5% to 4.0%. Adjusted EBITDA margin prior to Medicare cap is estimated to be 15.0% to 15.5%. Roto-Rooter expects full-year 2012 revenue growth of 2.0% to 4.0%. The revenue estimate is a result of increased pricing of approximately 2.0%, a favorable mix shift to higher revenue jobs, with job count estimated to range between down 1.0% to up 1.0%. Adjusted EBITDA margin for 2012 is estimated to be in the range of 16.5% to 17.5%. We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

### Financial Condition

### Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2011 to March 31, 2012 include the following:

- A $32.7 million increase in accounts receivable related to the timing of payments.
- A $4.8 million increase in accounts payable related to timing of payments.
- A $13.2 million increase in income taxes payable related to timing of payments.
- A $5.3 million decrease in accrued compensation related to the timing of payments of incentive compensation.

-16-

Net cash provided by operating activities decreased by $38.2 million due primarily to the change in accounts receivable partially offset by the change in income taxes. Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $29.4 million in standby letters of credit as of March 31, 2012, for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of March 31, 2012, we have approximately $320.6 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the $150 million expansion feature. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

### Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2012 and anticipate remaining in compliance throughout 2012.

On March 1, 2010 Anthony Morangelli and Frank Ercole filed a class action lawsuit in federal district court for the Eastern District of New York seeking unpaid minimum wages and overtime service technician compensation from Roto-Rooter and Chemed. They also seek payment of penalties, interest and plaintiffs’ attorney fees. We contest these allegations. In September 2010, the Court conditionally certified a nationwide class of service technicians, excluding those who signed dispute resolution agreements in which they agreed to arbitrate claims arising out of their employment. We are unable to estimate our potential liability, if any, with respect to this case.

VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White. This case alleges failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives. The case seeks payment of penalties, interest and Plaintiffs’ attorney fees. We contest these allegations. In December 2009, the trial court denied Plaintiffs’ motion for class certification. In July 2011, the Court of Appeals affirmed denial of class certification on the travel time, meal and rest period claims, and reversed the trial court’s denial on the off-the-clock and sales representation exemption claims. Plaintiffs have filed an appeal of this decision. We are unable to estimate our potential liability or potential range of loss, if any, with respect to this case.

On November 14, 2011 Luann and Michael Cosgrove and Dawn Mills filed a class action lawsuit against Roto-Rooter in Minnesota state district court for the 4th Judicial District alleging unnecessary excavation work in Minnesota. We removed the case to federal court. Plaintiffs seek damages, injunctive relief, attorney fees and interest. We contest these allegations. This lawsuit is in its early stage and we are unable to estimate our potential liability, if any, with respect to these allegations.

On January 12, 2012, the Greater Pennsylvania Carpenters Pension Fund filed a putative class action lawsuit in the United States District Court for the Southern District of Ohio against the Company, Kevin McNamara, David Williams, and Tim O’Toole. It alleges violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 against all defendants, and violation of Section 20(a) of the Securities Exchange Act of 1934 against the individual defendants. The suit, Greater Pennsylvania Carpenters Pension Fund v. Chemed Corp., et al., Civil Action No. 1:12-cv-28 (S.D. Ohio), concerns the VITAS hospice segment of the Company's business. Plaintiff seeks, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and November 16, 2011, compensatory damages in an unspecified amount and attorneys' fees and expenses, arising from defendants' failure to disclose an alleged fraudulent scheme to enroll ineligible hospice patients and to fraudulently obtain payments from the federal government. Defendants believe the allegations are without merit, and intend to defend vigorously against them.

Regardless of outcome, defense of litigation adversely affects us through defense costs, diversion of our time and related publicity.

-17-

In May 2009, VITAS received an administrative subpoena from the U.S. Department of Justice requesting VITAS deliver to the OIG documents, patient records, and policy and procedure manuals for headquarters and its Texas programs concerning hospice services provided for the period January 1, 2003 to the date of the letter. In August 2009, the OIG selected medical records for 59 past and current patients from a Texas program for review. In February 2010, VITAS received a companion civil investigative demand (“CID”) from the State of Texas Attorney General’s Office, seeking related documents. In September 2010, it received a second CID and a second administrative subpoena seeking related documents. In April 2011, the U.S. Attorney provided the Company with a copy of qui tam complaint filed under seal in the U.S. District Court for the Northern District of Texas. The Court unsealed this complaint in November 2011. The U.S. Attorney and the Attorney General for the State of Texas filed a notice in November 2011 that they had decided not to intervene at that time in the case. They continue to investigate its allegations. It was brought by Michael Rehfelt, a former Vitas San Antonio program general manager, against Vitas, the program’s former Regional Vice President Keith Becker, its former Medical Director Justos Cisneros, and their current employers: Wellmed Medical Management, Care Level Management LLC, and Inspiris Inc. Plaintiff dismissed his case against their current employers in March of 2012. The case alleges admission and recertification of inappropriate patients, backdating revocations, and conspiring to admit inappropriate patients to hospice. In June 2011, the U.S. Attorney provided the Company with a partially unsealed second qui tam complaint filed under seal in the U.S. District court for the Western District of Texas. In June 2011, the U.S. Attorney also provided the Company with a partially unsealed third qui tam complaint filed under seal in the Northern District of Illinois, Eastern Division. We are conferring with the U.S. Attorney regarding the Company’s defenses to each complaint’s allegations. We can neither predict the outcome of this investigation nor estimate our potential liability, if any. We believe that we are in compliance with Medicare and Medicaid rules and regulations applicable to hospice providers.

In April 2005, the Office of Inspector General (“OIG”) for the Department of Health and Human Services served VITAS with civil subpoenas relating to VITAS’ alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from VITAS’ three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information from us. The Court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs appealed this dismissal, which the Court of Appeals affirmed. The government continues to investigate the complaint’s allegations. In March 2009, we received a letter from the government reiterating the basis of their investigation. We are unable to estimate our potential liability, if any, with respect to this matter.

The costs to comply with either of these investigations were not material for any period presented. Regardless of outcome, responding to the subpoenas can adversely affect us through defense costs, diversion of our time and related publicity.

R**esults of Operations**

### Three months ended March 31, 2012 versus 2011 - Consolidated Results

Our service revenues and sales for the first quarter of 2012 increased 6.7% versus services and sales revenues for the first quarter of 2011. Of this increase, $25.2 million was attributable to VITAS partially offset by a $3.1 million decrease at Roto-Rooter. The following chart shows the components of those changes (dollar amounts in thousands):

| VITAS | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| Routine homecare | $17,945 | 10.6 |
| Continuous care | 3,896 | 10.1 |
| General inpatient | 1,766 | 6.4 |
| Medicare cap | 1,567 | 155.1 |
| Roto-Rooter |  |  |
| Plumbing | (1,364) | -3.0 |
| Drain cleaning | (1,581) | -4.3 |
| Contractor operations | 170 | 2.6 |
| Other | (374) | -5.4 |
| Total | $22,025 | 6.7 |

The increase in VITAS’ revenues for the first quarter of 2012 versus the first quarter of 2011 was a result of increased ADC of 6.1% driven by an increase in admissions of 3.3% and a 4.4% increase in average length of stay, combined with Medicare reimbursement rate increases of approximately 2.5%. The ADC increase was driven by a 6.2% increase in routine homecare, an increase of 4.9% in general inpatient and an increase of a 4.8% in continuous care. In excess of 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

-18-

The decrease in plumbing revenues for the first quarter of 2012 versus 2011 is attributable to a 2.1% decrease in the number of jobs performed as well as a 1.2% decrease in the average price per job. Our excavation job count increased by 6.3% compared to 2011. Drain cleaning revenues for the first quarter of 2012 versus 2011 reflect a 8.0% decrease in the number of jobs perfomed partially offset by a 4.0% increase in the price per job. Contractor operations revenue increased 2.6% for the first quarter of 2012.

The consolidated gross margin was 27.1% in the first quarter of 2012 as compared with 28.2% in the first quarter of 2011. On a segment basis, VITAS’ gross margin was 21.2% in the first quarter of 2012 and 21.8% in the first quarter of 2011. The decrease in VITAS’ gross margin is attributable to higher labor costs for admissions and Medicare compliance personnel and the opening of new operations, both new locations and new inpatient units, which carry significant start-up costs as capacity begins to ramp-up. The Roto-Rooter segment’s gross margin was 43.7% for the first quarter of 2012 as compared with 44.2% for the first quarter of 2011. The decrease in Roto-Rooter’s gross margin is mainly the result of the decrease in revenue.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

| SG&A expenses before long-term incentive compensation and the impact of market gains and | Three months ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| losses of deferred compensation plans | **$51,034** | $50,578 |
| Long-term incentive compensation | **-** | 3,012 |
| Impact of market value gains on liabilities held in |  |  |
| deferred compensation trusts | **2,133** | 2,064 |
| Total SG&A expenses | **$53,167** | $55,654 |

Normal salary increases and revenue related expense increases between periods accounts for the 0.9% increase in SG&A expenses before long-term incentive compensation and the impact of market gains of deferred compensation plans.

Interest expense increased 11.5% between periods as a result of the debt refinancing that took place in the first quarter of 2011.

Other income/(expense) comprise (in thousands):

| Market value gains on assets held in deferred | Three months ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| compensation trusts | **$2,133** | $2,064 |
| Loss on disposal of property and equipment | **(81)** | (21) |
| Interest income | **51** | 61 |
| Other | **(8)** | (2) |
| Total other income | **$2,095** | $2,102 |

Our effective income tax rate increased to 38.9% in the first quarter of 2012 from 38.4% when compared with the first quarter of 2011.

-19-

Net income for both periods included the following after-tax items/adjustments that reduced after-tax earnings (in thousands):

| VITAS | Three months ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| Legal expenses of OIG investigation | **$(44)** | $(317) |
| Acquisition expenses | **-** | (40) |
| Roto-Rooter |  |  |
| Expenses of class action litigation | **(393)** | (301) |
| Acquisition expenses | **(9)** | (4) |
| Corporate |  |  |
| Stock option expense | **(1,225)** | (1,223) |
| Noncash impact of change in accounting for convertible debt | **(1,224)** | (1,132) |
| Long-term incentive compensation | **-** | (1,880) |
| Total | **$(2,895)** | $(4,897) |

### Three months ended March 31, 2012 versus 2011 - Segment Results

The change in after-tax earnings for the first quarter of 2012 versus the first quarter of 2011 is due to (dollars in thousands):

|  | Increase/(Decrease) Amount | Percent |
| --- | ---: | ---: |
| VITAS | $1,502 | 8.3 |
| Roto-Rooter | (1,015) | -11.9 |
| Corporate | 1,857 | 21.8 |
|  | $2,344 | 12.9 |

-20-

### CHEMED CORPORATION AND SUBSIDIARY COMPANIES

### CONSOLIDATING STATEMENT OF INCOME

### FOR THE THREE MONTHS ENDED MARCH 31, 2012

(in thousands)(unaudited)

| 2012 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $260,847 | $92,096 | $- | $352,943 |
| Cost of services provided and goods sold | 205,620 | 51,825 | - | 257,445 |
| Selling, general and administrative expenses | 19,748 | 26,153 | 7,266 | 53,167 |
| Depreciation | 4,025 | 2,085 | 131 | 6,241 |
| Amortization | 490 | 154 | 469 | 1,113 |
| Total costs and expenses | 229,883 | 80,217 | 7,866 | 317,966 |
| Income/(loss) from operations | 30,964 | 11,879 | (7,866) | 34,977 |
| Interest expense | (62) | (108) | (3,447) | (3,617) |
| Intercompany interest income/(expense) | 755 | 395 | (1,150) | - |
| Other income/(expense)—net | (31) | (20) | 2,146 | 2,095 |
| Income/(expense) before income taxes | 31,626 | 12,146 | (10,317) | 33,455 |
| Income taxes | (11,999) | (4,650) | 3,639 | (13,010) |
| Net income/(loss) | $19,627 | $7,496 | $(6,678) | $20,445 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |

| Pretax benefit/(cost): | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Stock option expense | $- | $- | $(1,938) | $(1,938) |
| Noncash impact of accounting for convertible debt | - | - | (1,935) | (1,935) |
| Expenses of class action litigation | - | (647) | - | (647) |
| Acquisition expenses | - | (15) | - | (15) |
| Legal expenses of OIG investigation | (71) | - | - | (71) |
| Total | $(71) | $(662) | $(3,873) | $(4,606) |

| After-tax benefit/(cost): | VITAS | Roto-Rooter | Corporate | Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Stock option expense | $- | $- | $(1,224) | $(1,224) |
| Noncash impact of accounting for convertible debt | - | - | (1,225) | (1,225) |
| Expenses of class action litigation | - | (393) | - | (393) |
| Acquisition expenses | - | (9) | - | (9) |
| Legal expenses of OIG investigation | (44) | - | - | (44) |
| Total | $(44) | $(402) | $(2,449) | $(2,895) |

-21-

### CHEMED CORPORATION AND SUBSIDIARY COMPANIES

### CONSOLIDATING STATEMENT OF INCOME

### FOR THE THREE MONTHS ENDED MARCH 31, 2011

(in thousands)(unaudited)

| 2011 (a) | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Service revenues and sales | $235,673 | $95,245 | $- | $330,918 |
| Cost of services provided and goods sold | 184,300 | 53,158 | - | 237,458 |
| Selling, general and administrative expenses | 18,711 | 26,740 | 10,203 | 55,654 |
| Depreciation | 4,167 | 1,984 | 137 | 6,288 |
| Amortization | 483 | 132 | 355 | 970 |
| Total costs and expenses | 207,661 | 82,014 | 10,695 | 300,370 |
| Income/(loss) from operations | 28,012 | 13,231 | (10,695) | 30,548 |
| Interest expense | (48) | (64) | (3,132) | (3,244) |
| Intercompany interest income/(expense) | 1,213 | 639 | (1,852) | - |
| Other income/(expense)—net | 30 | (9) | 2,081 | 2,102 |
| Income/(expense) before income taxes | 29,207 | 13,797 | (13,598) | 29,406 |
| Income taxes | (11,082) | (5,286) | 5,063 | (11,305) |
| Net income/(loss) | $18,125 | $8,511 | $(8,535) | $18,101 |
| (a) The following amounts are included in net income (in thousands): |  |  |  |  |

| Pretax benefit/(cost): | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Long-term incentive compensation | $- | $- | $(3,012) | $(3,012) |
| Stock option expense | - | - | (1,933) | (1,933) |
| Noncash impact of accounting for convertible debt | - | - | (1,790) | (1,790) |
| Expenses of class action litigation | - | (495) | - | (495) |
| Acquisition expenses | (64) | (6) | - | (70) |
| Legal expenses of OIG investigation | (511) | - | - | (511) |
| Total | $(575) | $(501) | $(6,735) | $(7,811) |

| After-tax benefit/(cost): | VITAS | Roto-Rooter | Corporate | Consolidated |
| --- | ---: | ---: | ---: | ---: |
| Long-term incentive compensation | $- | $- | $(1,880) | $(1,880) |
| Stock option expense | - | - | (1,223) | (1,223) |
| Noncash impact of accounting for convertible debt | - | - | (1,132) | (1,132) |
| Expenses of class action litigation | - | (301) | - | (301) |
| Acquisition expenses | (40) | (4) | - | (44) |
| Legal expenses of OIG investigation | (317) | - | - | (317) |
| Total | $(357) | $(305) | $(4,235) | $(4,897) |

-22-

*Consolidating Summary and Reconciliation of Adjusted EBITDA*

*(in thousands)*

| Chemed Corporation and Subsidiary Companies For the three months ended March 31, 2012 | VITAS | Roto-Rooter | Corporate | Chemed Consolidated |
| --- | ---: | ---: | ---: | ---: |
| **Net income/(loss)** | $19,627 | $7,496 | $(6,678) | $20,445 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 62 | 108 | 3,447 | 3,617 |
| Income taxes | 11,999 | 4,650 | (3,639) | 13,010 |
| Depreciation | 4,025 | 2,085 | 131 | 6,241 |
| Amortization | 490 | 154 | 469 | 1,113 |
| **EBITDA** | 36,203 | 14,493 | (6,270) | 44,426 |
| Add/(deduct): |  |  |  |  |
| Legal expenses of OIG investigation | 71 | - | - | 71 |
| Acquisition expenses | - | 15 | - | 15 |
| Expenses of class action litigation | - | 647 | - | 647 |
| Stock option expense | - | - | 1,938 | 1,938 |
| Advertising cost adjustment | - | (706) | - | (706) |
| Interest income | (30) | (8) | (13) | (51) |
| Intercompany interest income/(expense) | (755) | (395) | 1,150 | - |
| **Adjusted EBITDA** | $35,489 | $14,046 | $(3,195) | $46,340 |
|  |  |  |  | Chemed |
| For the three months ended March 31, 2011 | VITAS | Roto-Rooter | Corporate | Consolidated |
| **Net income/(loss)** | $18,125 | $8,511 | $(8,535) | $18,101 |
| Add/(deduct): |  |  |  |  |
| Interest expense | 48 | 64 | 3,132 | 3,244 |
| Income taxes | 11,082 | 5,286 | (5,063) | 11,305 |
| Depreciation | 4,167 | 1,984 | 137 | 6,288 |
| Amortization | 483 | 132 | 355 | 970 |
| **EBITDA** | 33,905 | 15,977 | (9,974) | 39,908 |
| Add/(deduct): |  |  |  |  |
| Legal expenses of OIG investigation | 511 | - | - | 511 |
| Acquisition expenses | 64 | 6 | - | 70 |
| Expenses of class action litigation | - | 495 | - | 495 |
| Long-term incentive compensation | - | - | 3,012 | 3,012 |
| Stock option expense | - | - | 1,933 | 1,933 |
| Advertising cost adjustment | - | (250) | - | (250) |
| Interest income | (37) | (7) | (17) | (61) |
| Intercompany interest income/(expense) | (1,213) | (639) | 1,852 | - |
| **Adjusted EBITDA** | $33,230 | $15,582 | $(3,194) | $45,618 |

-23-

### CHEMED CORPORATION AND SUBSIDIARY COMPANIES

### OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

| OPERATING STATISTICS Net revenue ($000) | Three Months Ended March 31, 2012 | 2011 |
| --- | ---: | ---: |
| Homecare | **$186,597** | $168,652 |
| Inpatient | **29,152** | 27,386 |
| Continuous care | **42,521** | 38,625 |
| Total before Medicare cap allowance | **$258,270** | $234,663 |
| Medicare cap allowance | **2,577** | 1,010 |
| Total | **$260,847** | $235,673 |
| Net revenue as a percent of total |  |  |
| before Medicare cap allowance |  |  |
| Homecare | **72.2%** | 71.8% |
| Inpatient | **11.3** | 11.7 |
| Continuous care | **16.5** | 16.5 |
| Total before Medicare cap allowance | **100.0** | 100.0 |
| Medicare cap allowance | **1.0** | 0.4 |
| Total | **101.0%** | 100.4% |
| Average daily census (days) |  |  |
| Homecare | **9,613** | 8,833 |
| Nursing home | **2,986** | 3,033 |
| Routine homecare | **12,599** | 11,866 |
| Inpatient | **472** | 450 |
| Continuous care | **632** | 603 |
| Total | **13,703** | 12,919 |
| Total Admissions | **16,322** | 15,798 |
| Total Discharges | **16,196** | 15,552 |
| Average length of stay (days) | **82.4** | 78.9 |
| Median length of stay (days) | **14.0** | 13.0 |
| ADC by major diagnosis |  |  |
| Neurological | **34.2%** | 34.0% |
| Cancer | **17.9** | 17.9 |
| Cardio | **11.6** | 11.8 |
| Respiratory | **6.6** | 6.7 |
| Other | **29.7** | 29.6 |
| Total | **100.0%** | 100.0% |
| Admissions by major diagnosis |  |  |
| Neurological | **19.6%** | 19.5% |
| Cancer | **32.1** | 31.7 |
| Cardio | **11.8** | 11.1 |
| Respiratory | **8.7** | 9.1 |
| Other | **27.8** | 28.6 |
| Total | **100.0%** | 100.0% |
| Direct patient care margins |  |  |
| Routine homecare | **50.4%** | 51.1% |
| Inpatient | **14.1** | 13.0 |
| Continuous care | **19.9** | 20.5 |
| Homecare margin drivers (dollars per patient day) |  |  |
| Labor costs | **$57.76** | $55.38 |
| Drug costs | **8.33** | 7.97 |
| Home medical equipment | **6.82** | 6.66 |
| Medical supplies | **2.75** | 2.76 |
| Inpatient margin drivers (dollars per patient day) |  |  |
| Labor costs | **$314.34** | $306.66 |
| Continuous care margin drivers (dollars per patient day) |  |  |
| Labor costs | **$569.54** | $544.16 |
| Bad debt expense as a percent of revenues | **0.8%** | 0.6% |
| Accounts receivable -- |  |  |
| Days of revenue outstanding- excluding unapplied Medicare payments | **36.6** | 55.3 |
| Days of revenue outstanding- including unapplied Medicare payments | **30.8** | 29.1 |

-24-

### Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

## Market risk

As filed, 293 characters.

Our primary market risk exposure relates to interest rate risk exposure through variable interest rate borrowings. At March 31, 2012, we had no variable rate debt outstanding. At March 31, 2012, the fair value of the Notes approximates $191.4 million which have a face value of $187.0 million.

## Controls and procedures

As filed, 900 characters.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 135 characters.

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Filed Apr 30, 2012.
Source: SEC EDGAR, the filing index for accession 0001157523-12-002249. Last ingested by Listed: Nov 14, 2026, 12:29 ET. No prices; not investment advice.
